UNSPSC 51321817: Cetaben sodium

This classification denotes an anti-lipidemic agent with the molecular formula C23H38NO2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 433YPU24B8, chemically known as cl 203,821 but more generally known as cetaben sodium, which bears US NIH Compound Identifier 47262. Most nations, for tariff and trade purposes, schedule cetaben sodium under HS 29224995 and SITC 51465. As of Q4 2014, CETABEN SODIUM remains US FDA's Preferred Term for this commodity.

Cetaben sodium bears US NLM identifiers UMLS ID C2347605 and NCI Concept Code C72984. SMILES: CCCCCCCCCCCCCCCCNC1CCC(CC1)C(=O)[O-].[NA+].

UNSPSC 51321817 Cetaben sodium is a Commodity code that encompasses emergency pharmaceuticals and injectable medications procured by state and local health systems, fire departments, and state pharmacy benefit programs. Recent state and local solicitations show activity centered on advanced life support medications, generic multi-source pharmaceuticals for statewide distribution networks, and direct-to-manufacturer prescription sourcing strategies. The code's scope reflects procurement of specific drug formulations identified by National Drug Code (NDC), strength, dosage form, and packaging configuration, with vendors responsible for maintaining expiration dates, coordinating distribution through authorized wholesalers or direct supply chains, and ensuring FDA compliance and current Good Manufacturing Practices (cGMP) certification. Issuing bodies include municipal fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating procurement across multiple states and local government facilities.

The code shows recent activity in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, soliciting Advanced Life Support Medications for Tampa Fire Rescue with a response deadline of April 8, 2026 and an estimated contract value of $40,000 (note: due date precedes posting date in source); the solicitation named four specific injectable medications — Labetalol HCI, Epinephrine, Adenosine, and Diltiazem — with firm pricing, nine-month minimum expiration dates, and a one-year term with renewal options. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products on January 20, 2026, with a response deadline of March 26, 2026, requiring vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) across participating state and local government facilities including Oregon. The Texas Health and Human Services Commission issued an exploratory RFI on April 3, 2026, to assess vendor capabilities for implementing a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels.